PATH vs RXST
Uipath Inc (PATH) versus Rxsight Inc (RXST) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Rxsight Inc (RXST) is a medical devices company listed on NASDAQ.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Latest reported RXST revenue for 2024-12-31 was $139.9M. Net income was -$27.5M. Revenue was up 57.1% from 2023-12-31 to 2024-12-31. RXST currently screens at market cap $198.3M.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. RXST currently screens at market cap $198.3M.
Not investment advice. Open the PATH and RXST stock pages for the full models.
Not investment advice.